Tioma Therapeutics has generated a portfolio of anti-CD47 antibodies that have the potential to surmount multiple checkpoints by which cancer evades the immune system. These antibodies are protected by a strong, multilayered intellectual property estate that includes composition-of-matter and uses of humanized anti-CD47 antibodies.
Market
Cancer Immunotherapy
Location
Brisbane,
California,
USA
Coinvestors
Novo Ventures, RiverVest Venture Partners, Roche Venture Fund, SR One